Hong Kong-based biotech firm Immuno Cure BioTech (Immuno Cure) announced Thursday that it has closed the $12 million tranche in the $27 million Series A fundraising round. Led by the AEF Greater Bay Area Fund that Gobi Partners GBA (Gobi GBA) manages, this round will be used to accelerate the development of DNA vaccines and antibodies, as well as to prepare for an initial public offering (IPO) in Hong Kong.